Postoperative mortality in patients with end-stage renal disease according to the use of sugammadex: a single-center retrospective propensity score matched study

Sanghoon Song¹, Ho Bum Cho¹, Sun Young Park¹, Wan Mo Koo¹, Sang Jin Choi¹, Sokyung Yoon², Suyeon Park³, Jae Hwa Yoo¹, Mun Gyu Kim¹, Ji Won Chung¹, and Sang Ho Kim¹

Departments of ¹Anesthesiology and Pain Medicine, ²General Surgery, Soonchunhyang University Hospital Seoul, Seoul, ³Department of Biostatistics, Soonchunhyang University College of Medicine, Cheonan, Korea

Background: Clearance of the sugammadex-rocuronium complex is limited to renal excretion. There are restrictions on the use of sugammadex in patients with severe renal impairment. A paucity of data supports the clinical safety of sugammadex in patients with renal impairment. We analyzed mortality after using sugammadex in patients with end-stage renal disease to establish evidence of safety for sugammadex.

Methods: We retrospectively collected the medical records of 2,134 patients with end-stage renal disease who were dependent on hemodialysis and underwent surgery under general anesthesia between January 2018 and December 2019. Propensity score matching was used. The primary outcome was the 30-day mortality rate, and secondary outcomes were the 1-year mortality rate and causes of death.

Results: A total of 2,039 patients were included in the study. Sugammadex was administered as a reversal agent for rocuronium in 806 (39.5%) patients; the remaining 1,233 (60.5%) patients did not receive sugammadex. After matching, 1,594 patients were analyzed; 28 (3.5%) of the 797 patients administered sugammadex, and 28 (3.5%) of the 797 patients without sugammadex, died within 30 days after surgery (P > 0.99); 38 (4.8%) of the 797 patients administered sugammadex, and 45 (5.7%) of the 797 patients without sugammadex, died within 1 year after surgery (P = 0.499). No significant differences in the causes of 30-day mortality were observed between the two groups after matching (P = 0.860).

Conclusions: In this retrospective study, sugammadex did not increase the 30-day and 1-year mortality rate after surgery in end-stage renal disease patients.

Keywords: Dialysis; End-stage renal disease; Mortality; Neuromuscular blockade; Sugammadex.
INTRODUCTION

Sugammadex (Bridion, Merck Sharp and Dohme Corp., USA) is a reversal agent for steroidal neuromuscular blocking agents, such as rocuronium and vecuronium [1]. This drug directly reverses the neuromuscular-blocking effect of rocuronium by encapsulating the drug molecules. Any depth of neuromuscular blockade is reversed by an effective dose of sugammadex [2,3]. Conventional reversal agents, such as acetylcholinesterase inhibitors, do not have a direct reversal effect; these agents inhibit the breakdown of acetylcholine at the neuromuscular junction and thus indirectly enhance recovery from neuromuscular blockade [4]. Sugammadex is the only complete antagonist for rocuronium and vecuronium.

Sugammadex is not metabolized at all or only minimally metabolized, and is excreted rapidly by the kidney in healthy patients [5]. Highly significant correlations have been reported between plasma sugammadex and creatinine clearance, and between rocuronium and creatinine clearance in patients administered with rocuronium and sugammadex [6]. Rocuronium is eliminated by biliary and renal excretion, but clearance of rocuronium is limited to renal excretion when encapsulated by sugammadex [2].

The US Food and Drug Administration does not recommend the use of sugammadex in patients with severe renal impairment [7]. Although high-flux dialysis effectively removes sugammadex and the sugammadex–rocuronium complex, low-flux dialysis, which is a less common form of dialysis, does not significantly reduce the plasma concentration of sugammadex [5,8,9]. Therefore, reactivation of rocuronium due to dissociation of the rocuronium–sugammadex complex, the reappearance of neuromuscular blocking, and other as-yet-unknown adverse effects of residual sugammadex in plasma, such as long-term adverse immunological effects, are matters of concern. Several studies have been performed on the safety and efficacy of sugammadex in patients with renal impairment [10–15]. Despite the concerns described previously, clinicians often use sugammadex in patients with end-stage renal disease (ESRD) due to the benefits of sugammadex and based on several studies demonstrating its safety in patients with ESRD. This study was conducted to establish further evidence of the safety of sugammadex in patients with ESRD, by comparing 30-day mortality after surgery between the patients who received sugammadex and those who did not.

MATERIALS AND METHODS

The Institutional Review Board (IRB) approved this retrospective observational study (no. SCHUH 2020-08-007). The data analysis plan was filed with the IRB before any data were accessed. The requirement for informed consent was waived because of the retrospective study design. This article follows the Strengthening the Reporting of Observational Studies in Epidemiology guidelines [16].

We retrospectively collected the medical records of all patients with ESRD aged 18–90 years who were dependent on hemodialysis and underwent surgery under general anesthesia at a university hospital between January 2018 and December 2019. Patients who underwent emergency, cancer, cardiac, or transplantation surgery were excluded. The last surgery was included in the analysis when patients underwent multiple surgeries during the study period.

A total of 2,134 patients were eligible for this study, and their electronic medical records of the hospital were reviewed. Data on demographics (age, sex, and body mass index), preoperative laboratory tests (hemoglobin, platelet, international normalized ratio, activated partial thromboplastin time, blood urea nitrogen, creatinine, plasma sodium [Na], plasma potassium [K], plasma chloride [Cl], plasma albumin, plasma calcium [Ca], plasma phosphorus [P], hemoglobin A1c, aspartate aminotransferase [AST], and alanine aminotransferase [ALT]), comorbidities (hypertension, atrial fibrillation, current angina, previous myocardial infarction [MI], previous congestive heart failure, valvular heart disease, dilated cardiomyopathy, previous cerebrovascular attack, chronic obstructive pulmonary disease, and diabetes mellitus), left ventricular ejection fraction, anesthetic duration, the volume of intraoperative crystalloids, colloids administered, and blood loss, intraoperative transfusion, and packed red blood cells unit of transfusion were collected. The preoperative laboratory tests were conducted after dialysis. Patients who received sugammadex were included in the sugammadex group, and those who did not were included in the non-sugammadex group. The primary outcome was 30-day mortality according to the sugammadex administration, and the secondary outcomes were the 1-year mortality rate and causes of death according to the sugammadex administration. Mortality data were obtained from patient electronic medical records, and by submitting a data request to the Korean National Statistical Office (Microdata Integrated Service: https://mdis.kostat.go.kr). The mortality data of citizens of the Republic of Korea are compre-
hensively managed through resident registration numbers, as reflected in our statistics.

Our institution has a general anesthetic protocol. After placing the patient on the operating table, devices for electrocardiography, pulse oximetry, noninvasive blood pressure monitoring, neuromuscular transmission (NMT, General Electric Healthcare, Finland), and the bispectral index (BIS, Aspect Medical Systems, USA) were attached. Volatile anesthesia or total intravenous anesthesia was selected by the assigned anesthesiologist.

Volatile anesthesia was induced with 2% lidocaine (40 mg), 1% propofol (1–1.5 mg/kg), and rocuronium (0.6 mg/kg); if needed, remifentanil was administered using a target-controlled infusion system (Orchestra Primea, Fresenius Kabi AG, Germany) at a concentration of 0–6 ng/ml. Sevoflurane or desflurane was used for maintenance, and their doses were adjusted to maintain a BIS value of 40–60.

In cases of total intravenous anesthesia, 2% propofol and remifentanil were used to induce and maintain anesthesia using a target-controlled infusion system; the same regimen was used for lidocaine and rocuronium. The target-controlled infusion of propofol was adjusted (2–5 μg/ml) to maintain a BIS value of 40–60, and remifentanil was administered (0–6 ng/ml) during the operation. In both protocols, 4 mg of intravenous ephedrine or 50 μg of phenylephrine was used as necessary. Train-of-four monitoring using NMT continued throughout the whole period of anesthesia, but additional rocuronium was administered only when the patient moved or resisted mechanical ventilation, even if the train-of-four count exceeded 2. Fentanyl (0.3–0.5 μg/kg) was administered at the beginning of skin closure. At the end of the surgery, 0.2 mg/kg of pyridostigmine, and 5 μg/kg of glycopyrrolate or 1–2 mg/kg of sugammadex, was administered. The choice of reversal agent was at the discretion of the anesthesiologist. After confirmation of adequate reversal of neuromuscular blocking using NMT (train-of-four T4/T1 ratio of 0.9), the patient was extubated or the supraglottic airway was removed. After transfer to the post-anesthetic care unit, patients were observed for the presence of residual symptoms or the reappearance of neuromuscular blocking, and received an opioid or antiemetic as necessary. Patients transferred to the intensive care unit followed the post-operative patient management policy of the intensive care unit. Our institution uses only low-flux dialysis, and all patients received dialysis on postoperative day 0 or 1.

Patient demographics, comorbidities, laboratory test results, intraoperative recordings, and the 30-day and 1-year mortality rates were compared between the sugammadex and non-sugammadex groups using Mann–Whitney U test for continuous variables, and the chi-square (except for ‘dilated cardiomyopathy’) or Fisher’s exact test (only for ‘dilated cardiomyopathy’) for categorical data. The Shapiro–Wilk test was used to assess the normality of the data distribution.

The propensity score matching method was used to correct for selection bias and adjust for confounding factors [17]. The factors included were a history of hypertension, atrial fibrillation, current angina, previous MI, previous congestive heart failure, valvular heart disease, dilated cardiomyopathy, previous cerebrovascular attack, chronic obstructive pulmonary disease, diabetes mellitus, and variables with significant differences (P < 0.05) between the groups. First, the propensity score matching method was used to balance the covariates between the two groups. All patients were matched in a 1:1 ratio in order of nearest neighbor. The caliber of nearest neighbor matching was 0.1. At this time, it was evaluated using standard mean difference (SMD), and 0.1 was considered for the success of matching. Second, covariates with SMD values greater than 0.1 were used as adjustment variables for the final model. The SMD was used to evaluate the covariates; those with a SMD ≥ 0.1 were considered significant.

After confirming that the groups were well-matched, logistic regression was performed to determine whether sugammadex was associated with an increase in 30-day and 1-year mortality. If the SMD was ≥ 0.1 after propensity score matching, it was included in the final model as a covariate. The results of the univariable and multivariable logistic regression analyses are presented as odds ratios (ORs) with 95% confidence intervals (CIs). All statistical analyses were performed using Rex software (version 3.0.3, RexSoft Inc., Korea) [18] based on R (version 4.0.0, R Foundation for Statistical Computing, Austria), and a 2-sided P value < 0.05 was considered significant.

RESULTS

Among 2,134 patients with ESRD who underwent surgery under general anesthesia, 2,039 were enrolled in the analysis (Fig. 1). Sugammadex was administered as a reversal agent for rocuronium in 806 (39.5%) patients, while 1,233 (60.5%) patients did not receive sugammadex. During propensity score matching, 12 patients were excluded because of missing data, and 2,027 were included in the matching. After propensity score matching, 797 patients were assigned to
the sugammadex group and 797 patients to the non-sugammadex group (Fig. 1).

Table 1 shows the characteristics of the patients before and after propensity score matching, respectively. Age, sex, current angina, previous congestive heart failure, valvular heart disease, left ventricular ejection fraction, preoperative post-dialysis plasma K, Cl, albumin, and P, the amount of intraoperatively administered crystalloid, anesthetic duration and intraoperative transfusion were significantly different between the groups before matching. Because preoperative echocardiography was not performed in all patients, it was not considered in the matching process. No significant difference was observed between the groups after matching. As the number of patients who received blood transfusion was too small for propensity score matching, it was not considered in the matching process. As the number of patients who received blood transfusion was too small for propensity score matching, it was not included in the regression analysis. The SMD of factors with $P < 0.05$ (age, sex, plasma K, Cl, albumin and P, amount of intraoperatively administered crystalloid, and anesthetic duration) and of comorbidities (hypertension, atrial fibrillation, current angina, previous MI, previous congestive heart failure, valvular heart disease, dilated cardiomyopathy, previous cerebrovascular attack, chronic obstructive pulmonary disease, and diabetes mellitus) were calculated. The factors including a history of hypertension, atrial fibrillation, current angina, previous MI, previous congestive heart failure, valvular heart disease, dilated cardiomyopathy, previous cerebrovascular attack, chronic obstructive pulmonary disease, diabetes mellitus, and variables with significant differences ($P < 0.05$) between the groups [age, sex, plasma K, Cl, albumin, and P, amount of intraoperatively administered crystalloid, and anesthetic duration] were used in propensity score matching. After matching, all covariates except for the amount of intraoperatively administered crystalloid, anesthetic duration, and transfusion had a SMD < 0.1 in all 1,594 patients (Table 1, Supplementary Fig. 1).

Table 2 shows the 30-day and 1-year mortality rates of both groups before and after propensity score matching. No significant difference in the 30-day or 1-year mortality rate was observed between the two groups before or after match-
| Variables                              | Before propensity score matching (n = 2,039) | SMD | After propensity score matching (n = 1,594) | P value | SMD |
|----------------------------------------|---------------------------------------------|-----|--------------------------------------------|---------|-----|
|                                        | Sugammadex (n = 806)                        |     | Non-sugammadex (n = 1,233)                |         |     |
|                                        |                                             |     |                                             |         |     |
|                                        | 66 (55.75)                                 |     | 64 (55.74)                                 | 0.018†  | 0.088 |
|                                        | 444 (55.1)                                 |     | 613 (49.7)                                 | 0.020†  | 0.113^ |
|                                        | 23.1 (20.5, 25.6)                          |     | 22.7 (20.4, 25.6)                          | 0.065   |     |
|                                        | 666 (82.6)                                 |     | 1005 (81.5)                                | 0.559   | 0.032 |
|                                        | 57 (7.1)                                   |     | 67 (5.4)                                   | 0.156   | 0.065 |
|                                        | 62 (7.7)                                   |     | 54 (4.4)                                   | 0.002†  | 0.138^|
|                                        | 34 (4.2)                                   |     | 37 (3.0)                                   | 0.179   | 0.067 |
|                                        | 113 (14.0)                                 |     | 135 (11.0)                                 | 0.045‡  | 0.090 |
|                                        | 1 (0.1)                                    |     | 1 (0.8)                                    | > 0.99* | 0.014 |
|                                        | 63 (57.59)                                 |     | 64 (60.69)                                 | 0.023‡  |     |
|                                        | 134 (16.6)                                 |     | 177 (14.4)                                 | 0.183†  | 0.063 |
|                                        | 412 (51.1)                                 |     | 595 (48.3)                                 | 0.223   | 0.065 |
|                                        | 11.2 (10.1, 12.3)                          |     | 11.2 (10.2, 12.2)                          | 0.432   |     |
|                                        | 187 (144, 229)                             |     | 182 (144, 227)                             | 0.373   |     |
|                                        | 1.00 (0.94, 1.05)                          |     | 1.01 (0.95, 1.06)                          | 0.277   |     |
|                                        | 30.8 (28.2, 33.1)                          |     | 30.6 (28.2, 33.1)                          | 0.847   |     |
|                                        | 29.3 (16.6, 48.8)                          |     | 27.8 (17.4, 42.7)                          | 0.448   |     |
|                                        | 4.58 (2.37, 7.54)                          |     | 4.89 (3.14, 7.26)                          | 0.313   |     |
|                                        | 140 (139, 142)                             |     | 140 (138, 142)                             | 0.669   |     |
|                                        | 4.3 (3.9, 4.8)                             |     | 4.5 (4.4, 4.9)                             | < 0.001† | 0.185^ |
|                                        | 101 (98, 103)                              |     | 100 (98, 103)                              | 0.049†  | 0.104^ |
|                                        | 4.2 (3.7, 4.5)                             |     | 4.3 (3.9, 4.6)                             | 0.001‡  | 0.151^ |
|                                        | 4.0 (2.8, 5.1)                             |     | 4.2 (3.2, 5.3)                             | 0.023‡  | 0.172^ |
|                                        | 9.2 (8.7, 9.7)                             |     | 9.3 (8.8, 9.8)                             | 0.147   |     |
|                                        | 6.6 (5.9, 7.6)                             |     | 6.6 (5.8, 7.6)                             | 0.858   |     |
|                                        | 18 (15, 23)                                |     | 17 (14, 22)                                | 0.156   |     |
|                                        | 13 (9, 19)                                 |     | 13 (10, 18)                                | > 0.99  |     |
|                                        | 150 (100, 300)                             |     | 120 (100, 200)                             | < 0.001† | 0.341^ |
|                                        | 300 (200, 500)                             |     | 250 (150, 400)                             | 0.346   |     |
|                                        | 10 (0, 40)                                 |     | 20 (0, 50)                                 | 0.065   |     |
|                                        | 115 (85, 155)                              |     | 110 (85, 144)                              | 0.002‡  | 0.241^ |
|                                        | 12 (1.5)                                   |     | 6 (0.5)                                    | 0.032‡  |     |
|                                        | 2 (1.75, 3.25)                             |     | 1 (1, 1.75)                                | 0.167   |     |
|                                        | 66 (55.75)                                 |     | 66 (57.75)                                 | 0.448   | 0.050 |
|                                        | 440 (55.2)                                 |     | 451 (56.6)                                 | 0.614   | 0.028 |
|                                        | 23.1 (20.5, 25.9)                          |     | 22.8 (20.6, 25.7)                          | 0.318   |     |
|                                        | 659 (82.7)                                 |     | 661 (82.9)                                 | 0.947   | 0.007 |
|                                        | 56 (7.0)                                   |     | 52 (6.5)                                   | 0.765   | 0.020 |
|                                        | 61 (7.7)                                   |     | 52 (6.5)                                   | 0.435   | 0.044 |
|                                        | 34 (4.3)                                   |     | 32 (4.0)                                   | 0.900   | 0.013 |
|                                        | 28 (3.5)                                   |     | 22 (2.8)                                   | 0.472   | 0.043 |
|                                        | 113 (14.2)                                 |     | 118 (14.8)                                 | 0.776   | 0.018 |
|                                        | 1 (0.1)                                    |     | 1 (0.1)                                    | > 0.99* | < 0.001 |

Values are presented as median (1Q, 3Q) or number (%). Because preoperative echocardiography and assessment of hemoglobin A1c were not performed routinely, and colloids were not administered routinely, the number of patients with available data for these parameters is indicated. SMD: standardized mean difference, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction, Na: sodium, K: potassium, Cl: chloride, Ca: calcium, P: phosphorus, AST: aspartate aminotransferase, ALT: alanine aminotransferase, RBC: red blood cells. Continuous variables were analyzed using the Mann–Whitney U test, and categorical variables using the χ² test or *Fisher’s exact test. †P value < 0.05, ‡SMD > 0.1.
ing. After matching, 1,594 patients were analyzed; 28 (3.5%) of the 797 patients administered sugammadex, and 28 (3.5%) of the 797 patients without sugammadex, died within 30 days after surgery (P > 0.99); 38 (4.8%) of the 797 patients administered sugammadex, and 45 (5.7%) of the 797 patients without sugammadex, died within 1 year after surgery (P = 0.499) (Table 2). Additionally, no significant differences in the causes of 30-day mortality were observed between the two groups before matching (P = 0.982) or after matching (P = 0.860) (Fig. 2). The unadjusted OR of sugammadex for 30-day mortality was 1.01 (95% CI 0.59 to 1.72). The adjusted OR of sugammadex for 30-day mortality was 0.94 (95% CI 0.51 to 1.62), while for 1-year mortality it was 0.80 (95% CI 0.51 to 1.26) (Table 3).

Table 2. Comparison of 30-day and 1-year Mortality after Surgery between the Sugammadex and Non-sugammadex Groups Before and After Propensity Score Matching

| Variables                        | Total        | Sugammadex   | Non-sugammadex | P value |
|----------------------------------|--------------|--------------|----------------|---------|
| Before propensity score matching | n = 2,039    | n = 806      | n = 1,233      |         |
| 30-day mortality                 | 62 (3.0)     | 29 (3.6)     | 33 (2.7)       | 0.292   |
| 1-year mortality                 | 97 (4.7)     | 39 (4.8)     | 58 (4.7)       | 0.973   |
| After propensity score matching  | n = 1,594    | n = 797      | n = 797        |         |
| 30-day mortality                 | 56 (3.5)     | 28 (3.5)     | 28 (3.5)       | > 0.99  |
| 1-year mortality                 | 83 (5.2)     | 38 (4.8)     | 45 (5.7)       | 0.499   |

Values are presented as numbers of patients (%). Data were analyzed using the χ²-test.

Fig. 2. Comparison of the causes of 30-day mortality between the sugammadex and non-sugammadex groups before and after matching. It is difficult to differentiate the difference in distribution according to whether sugammadex is administered.
Table 3. ORs for 30-day and 1-year Mortality after Surgery according to the Use of Sugammadex after Propensity Score Matching

| Variables       | Univariable analysis | Multivariable analysis |
|-----------------|----------------------|------------------------|
|                 | Crude OR (95% CI)    | P value                | Adjusted OR (95% CI) | P value |
| 30-day mortality| 1.01 (0.59–1.72)     | 0.973                  | 0.94 (0.55–1.62)     | 0.827   |
| 1-year mortality| 0.84 (0.54–1.32)     | 0.455                  | 0.80 (0.51–1.26)     | 0.332   |

OR: odds ratio; CI: confidence interval. Adjusted by anesthetic duration, volume of intraoperative crystalloids administered, and intraoperative transfusion. Wald confidence intervals were calculated.

DISCUSSION

Sugammadex was not significantly associated with 30-day or 1-year mortality after surgery under general anesthesia in more than 1,500 patients with ESRD. Although we did not detect any benefit of sugammadex, we could suggest that sugammadex does not increase mortality until one year after surgery.

It was reported the efficacy and safety of sugammadex for moderate neuromuscular blockade in patients with ESRD. The time to achieve a train-of-four T1 ratio of 0.9 was no longer in patients with ESRD compared to normal controls, and 2 mg/kg sugammadex safely reversed the effects of rocuronium in patients with renal impairment [12]. However, efficacy and safety were only assessed 48 h after surgery and only for moderate neuromuscular blockade. In a later study, Staals et al. [6] reported that the plasma concentration of rocuronium did not differ between patients with severe renal impairment and controls before administering sugammadex. However, plasma clearance of rocuronium decreases significantly after administering sugammadex in patients with severe renal impairment [6]. Another study by Panhuizen et al. [11] demonstrated that 4 mg/kg sugammadex can safely and completely reverse neuromuscular blockade in patients with severe renal impairment, but recovery of the train-of-four T1 ratio took longer than in controls. And the rocuronium– sugammadex complex remained at detectable levels in plasma on day 7 [11]. When encapsulated by sugammadex, clearance of rocuronium is limited to renal excretion [2]. Therefore, anesthesiologists may be concerned about potential long-term adverse effects of sugammadex and the rocuronium–sugammadex complex, so may avoid using sugammadex in patients with ESRD. There is a controversy about whether sugammadex can reduce postoperative pulmonary complications; there are studies proving that sugammadex could not reduce postoperative pulmonary outcomes [19,20]; on the other side, a study revealed that sugammadex significantly reduced pulmonary complications compared to neostigmine, including pneumonia and respiratory failure [21]. However, these studies did not perform subgroup analyzes of a patient with an American Society of Anesthesiologists physical status of 3–5. In patients with an American Society of Anesthesiologists physical status of 3–4, sugammadex significantly reduces the negative impact of older age on pulmonary outcome scores compared to neostigmine [22]. Furthermore, extubation after achieving a higher train-of-four ratio had a beneficial effect on postoperative pulmonary complications, and a higher train-of-four ratio was achieved more easily and reliably with sugammadex than neostigmine [23,24]. Sugammadex might have potential benefits in terms of safety for high-risk patients with an American Society of Anesthesiologists physical status of ≥ 3. Additionally, a meta-analysis showed that sugammadex significantly decreases the risk of bradycardia, and postoperative nausea and vomiting, as well as signs of postoperative residual paralysis [25]. Therefore, sugammadex has certain advantages, and there is no evidence that it worsens the postoperative mortality outcomes of patients with ESRD, either from our study or several previous studies [10–12,14,15,24].

Chronic kidney disease is an independent risk factor for postoperative mortality and complications [26]. In addition, most patients with ESRD have multiple comorbidities, including cardiovascular disease and diabetes mellitus [27]. Considering their severe comorbidities, the baseline characteristics of patients with ESRD could be important factors in mortality after surgery and anesthesia. Therefore, we used propensity score matching to adjust for these factors. In addition to comorbidities, preoperative laboratory test results, including sodium, potassium, chloride, albumin, and phosphorus plasma concentrations, were included as potential confounding variables [28–30].

Some limitations of this study should be discussed. First, there was no standard protocol for the use of sugammadex, because of the retrospective design of the study. The anesthesiologists decided at their discretion between pyridostigmine and sugammadex as the reversal agent for neuromuscular blockade. Selection bias would be caused by the anes-
thesiologist tending to use sugammadex in fragile patients who cannot recover easily from neuromuscular blockade. However, the purpose of this study was to determine the safety of sugammadex. The potential selection bias further emphasizes the benefits of sugammadex, where there was no difference in mortality between the sugammadex and non-sugammadex groups. Second, no significant differences in the causes of postoperative death within 30 days were observed between the groups, but there were many cases with unclear causes, classified as ‘unknown’ or ‘end-stage renal disease.’ Cardiovascular events are well known as the major cause of death in patients with ESRD [26], but we could not confirm it due to the retrospective study design and incompleteness of the cause of death record. Third, the sample size was insufficient for good statistical power in this study. Because no previous studies have analyzed postoperative mortality in patients with ESRD according to the use of sugammadex, we could not calculate the required sample size. Based on our 30-day mortality data, the estimated required sample size was 5,801 for each group to achieve 80% power. Fourth, the type of surgery may also affect mortality, but we did not investigate the type. Finally, we could not report immediate postoperative pulmonary complications due to the nature of the study design. However, several studies have confirmed the short-term safety of sugammadex in patients with renal impairment [10–12,14], and one study reviewed 219 patients with chronic kidney disease stage 5 administered sugammadex which study suggested that sugammadex could be considered as an alternative reversal agent in patients with ESRD in aspects of complications and mortality within 30 postoperative days [15]. Outcomes of our study are only 30-day and 1-year mortality, but our study is a comparison study using the propensity score matching method, and the number of patients included in final analysis is 1,594.

In this retrospective analysis, sugammadex did not increase the 30-day and 1-year mortality rate in patients with ESRD after surgery under general anesthesia. Because it is a short-term study at a single center, there are limitations in applying it to all ESRD patients. Most patients with ESRD have multiple comorbidities and a high-risk status. Given the benefits of sugammadex in high-risk patients, we expect that sugammadex would be helpful in patients with ESRD.

**SUPPLEMENTARY MATERIALS**

Supplementary data including a “Standardized mean difference between the sugammadex and non-sugammadex groups” can be found online at https://doi.org/10.17085/apm.22189.

**FUNDING**

This research was supported by the Soonchunhyang University Research Fund (2017R1C1B5076787). And these institution was not involved in any part of the study.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**DATA AVAILABILITY STATEMENT**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**AUTHOR CONTRIBUTIONS**

Conceptualization: Sun Young Park, Wan Mo Koo. Data curation: Suyeon Park. Formal analysis: Suyeon Park. Methodology: Sokyung Yoon, Jae Hwa Yoo. Visualization: Ho Bum Cho. Writing - original draft: Sanghoon Song, Mun Gyu Kim. Writing - review & editing: Sanghoon Song. Investigation: Sang Jin Choi. Supervision: Ji Won Chung, Sang Ho Kim.

**ORCID**

Sanghoon Song, https://orcid.org/0000-0002-9327-2472
Ho Bum Cho, https://orcid.org/0000-0001-9540-1525
Sun Young Park, https://orcid.org/0000-0003-2588-3324
Wan Mo Koo, https://orcid.org/0000-0002-9898-142X
Sang Jin Choi, https://orcid.org/0000-0001-8065-882X
Sokyung Yoon, https://orcid.org/0000-0001-6004-664X
Suyeon Park, https://orcid.org/0000-0002-6391-557X
Jae Hwa Yoo, https://orcid.org/0000-0003-0675-0761
Mun Gyu Kim, https://orcid.org/0000-0003-1992-8215
Ji Won Chung, https://orcid.org/0000-0003-4573-9100
Sang Ho Kim, https://orcid.org/0000-0003-3781-5353

**REFERENCES**

1. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharma-
Sugammadex in ESRD patients

cology of sugammadex. J Crit Care 2009; 24: 29-35.
2. Giszenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
3. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41: 266-70.
4. Butterworth JF, Mackey DC, Wasnick JD. Morgan & Mikhail’s clinical anesthesiology. 6th ed. New York (NY), McGraw-Hill. 2018. p. 226-7.
5. Peeters P, Passier P, Smeets J, Zwierts A, de Zwart M, van de Wetering-Krebers S, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos 2011; 32: 159-67.
6. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104: 31-9.
7. Merck Sharp & Dohme. BRIDION® (sugammadex) injection, for intravenous use initial U.S. approval: 2015. U.S. Food and Drug Administration [Internet]. 2015 Dec 15 [updated 2016 Feb 16; cited 2020 Jul 15]. Available from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snap-shot-bridion.
8. Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth 2012; 109: 382-90.
9. Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006; 30: 895-7.
10. de Souza CM, Tardelli MA, Tedesco H, Garcia NN, Caparros MP, Alvarez-Gomez JA, et al. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: a comparative prospective clinical trial. Eur J Anaesthesiol 2015; 32: 681-6.
11. Panhuizen IF, Gold SJ, Buerkle C, Snoeck MM, Harper NJ, Kaspers MJ, et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Br J Anaesth 2015; 114: 777-84.
12. Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008; 101: 492-7.
13. Min KC, Lasseter KC, Marbury TC, Wrishko RE, Hanley WD, Woldford DG, et al. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment. Int J Clin Pharmacol Ther 2017; 55: 746-52.
14. Adams DR, Tollinche LE, Yeoh CB, Artman J, Mehta M, Phillips D, et al. Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. Anaesthesia 2020; 75: 348-52.
15. Paredes S, Porter SB, Porter IE 2nd, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. Can J Anaesth 2020; 67: 1789-97.
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573-7.
17. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
18. Rexsoft. Rex: excel-based statistical analysis software. Seoul, Rexsoft. 2018.
19. Li G, Freundlich RE, Gupta RK, Hayhurst CJ, Le CH, Martin BJ, et al. Postoperative pulmonary complications’ association with sugammadex versus neostigmine: a retrospective registry analysis. Anesthesiology 2021; 134: 862-73.
20. Kirmeyer E, Eriksson LI, Lewald H, Jonsson Fagerlund M, Hoeft A, Hollmann M, et al. POPULAR Contributors. Post-anesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med 2019; 7: 129-40. Erratum in: Lancet Respir Med 2019; 7: e9.
21. Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD, Colquhoun DA, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis. Anesthesiology 2020; 132: 1371-81.
22. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol 2014; 31: 423-9.
23. Blobner M, Hunter JM, Meistelman C, Hoeft A, Hollmann MW, Kirmeyer E, et al. Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR
24. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569-74.

25. Hristovska AM, Duch P, Allingstrup M, Afshari A. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2018; 73: 631-41.

26. Mathew A, Devereaux PJ, O’Hare A, Tonelli M, Thiessen-Phillbrook H, Nevis IF, et al. Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis. Kidney Int 2008; 73: 1069-81.

27. Saran R, Robinson B, Shahinian V. 2018 USRDS annual data report: executive summary. Bethesda (MD), United States Renal Data System. 2018.

28. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO\textsubscript{4}, Ca x PO\textsubscript{4} product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.

29. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, et al. Predictors of early mortality among incident US hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol 2007; 2: 89-99.

30. Bae MH, Lee JH, Yang DH, Park HS, Cho Y, Chae SC. Usefulness of surgical parameters as predictors of postoperative cardiac events in patients undergoing non-cardiac surgery. Circ J 2014; 78: 718-23.